BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection. BerGenBio's lead candidate, bemcentinib, is a once-a-day, oral, highly selective and potent inhibitor of AXL kinase, which has demonstrated a key role in cancer treatment by preventing immune evasion, drug resistance and metastasis in a variety of cancer trials.
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer. Cytovia’s proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site. Both platforms offer optionality to clinicians and can also be used synergistically. Cytovia’s R&D laboratories and GMP manufacturing facility are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, STC Biologics, and the University of California San Francisco (UCSF).
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies. https://www.markertherapeutics.com/
Phosplatin Therapeutics Inc.
Phosplatin Therapeutics is a privately held, clinical-stage pharmaceutical company currently in Phase 2 development of lead oncology candidate PT-112, a novel, small molecule immunogenic cell death (ICD) inducer, in disease settings with limited treatment options. PT-112 is the first pyrophosphate conjugate in oncology therapeutics and offers a unique combination of advantages. It is the best-in-class ICD inducer, with demonstrated durable single-agent activity, as well as synergy with PD-L1 immune checkpoint inhibition, and outstanding tolerability. PT-112 has a pleiotropic mechanism of action, avoids common drug resistance pathways and promotes immune cell infiltration in the tumor micro-environment.
PT-112’s compelling advantages include:
Best-in-class induction of ICD, a rare form of cancer cell death that elicits an adaptive immune response via specific damage signals and processing of cancer cell-associated antigens
Biodistribution includes affinity to bone (osteotropism), offering advantage in treating cancers with bone involvement; e.g., metastatic prostate, lung and breast cancers, and hematological malignancies
Limited cross-resistance with conventional therapy, with clinical responses observed in multi-refractory patients
Demonstrated synergy in combination with I-O checkpoint inhibitors
PT-112 clinical program:
Phase 2 study ongoing in metastatic castration-resistant prostate cancer, led by clinical investigators from Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana Farber Cancer Institute, Weill Cornell Medical and MD Anderson Cancer Center
Phase 2 study in thymoma/thymic carcinoma pending, a rare disease with no FDA-approved therapy; PT-112 holds Orphan Drug Designation
Phase 2a dose confirmation study in combination with PD-L1 inhibition ongoing in NSCLC; Phase 1b reported in mini-oral presentation at the European Society of Medical Oncology (ESMO) 2020
Phase 1 monotherapy study in multiple myeloma reported at the American Society of Hematology (ASH) 2020; PT-112 holds Orphan Drug Designation
Phase 1 monotherapy first-in-human study in solid tumors reported at ESMO (“Best Poster” winner, Developmental Therapeutics)
Ultimovacs (Euronext Oslo Stock Exchange: ULTI.OL) is a Norwegian biotech Company that is pursuing several Phase II clinical development trials in a number of cancer indications. The company is advancing its proprietary peptide-based universal cancer vaccine program, UV1. UV1 induces a specific T cell response against the universal cancer antigen telomerase (hTERT) and is made up of long, synthetic peptides shown to induce CD4+ T cells displaying a Th1 cytokine profile. With over 85% of tumors expressing hTERT at a high level, UV1 has the potential to treat a broad range of cancer indications.
To date, Ultimovacs has conducted multiple Phase I studies in different cancer indications with different inhibitor combinations, confirming the safety and tolerability of its proprietary vaccine. The company announced the initiation of four Phase II triple combination studies.
APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies and respiratory treatments.
Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.
APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and viral infections. The company has built a promising pipeline of drug candidates that target different TNFSF (tumor necrosis factor superfamily)-dependent signaling pathways, thereby restoring the immune response in diseased patients. Asunercept (CD95L inhibitor): Asunercept is in clinical development for the treatment of glioblastoma, myelodysplastic syndromes (MDS) and COVID-19. In a controlled phase II proof-of-concept trial in recurrent glioblastoma clinically efficacy has been achieved. Patients with a CD95 ligand related biomarker experienced a statistically significant overall survival benefit from treatment with Asunercept. The pivotal phase II/III trial in glioblastoma is in preparation to be discussed with regulatory agencies in EU and US. Asunercept has also being evaluated in a phase I trial for the treatment MDS, a stem cell disorder that leads to severe anemia. Data reveal an increase in erythrocyte precursor cells and a trend towards reduction of transfusion frequency in MDS patients. Results further confirm the safety and very good tolerability of Asunercept. A randomized Phase II study in COVID-19 patients is currently ongoing based on convincing scientific rationale and preclinical data. HERA-Ligands + Bispecifics: HERA-Ligands are a unique approach mimicking the trimeric natural structure of a TNF SF ligand leading to optimal receptor stimulation superior to other biologics such as antibodies. The lead program, HERA-TRAIL/ABBV-621 has been partnered with AbbVie who is currently running two PI studies in solid tumors. HERA-CD40L, HERA-CD27L and HERA-GITRL are in preclinical development with data showing superiority over other formats such as antibodies and are about 18 months to IND. Bispecific HERA-ligands combining the trimeric single-chain ligand with a targeting domain such as anti PD-L1 moieties are in preclinical development.
Ashvattha Therapeutics, a clinical-stage biopharmaceutical company, is developing novel therapeutics that target and alter specific cells in areas of diseased tissues. The Company’s targeted platform technology, hydroxyl dendrimers (HD), is exclusively licensed from Johns Hopkins University. HDs chemically conjugated to disease modifying drugs create novel proprietary HD therapeutics (HDTs). Ashvattha has initiated multiple programs with HDTs focused on neuro-oncology, neurology, age-related macular degeneration (AMD), and hyperinflammation in diseases such as COVID-19. Ashvattha has demonstrated the ability to take extremely potent, yet systemically toxic, compounds and eliminate off-target toxicity to achieve HDTs with high potency and efficacy in immune oncology applications. For example, HDTs consisting of a sunitinib analog, a Aurastatin E analog, and a TLR4 agonist have all been shown to be well tolerated at doses where the parent drug is lethal in animals. HDTs specifically target the tumor associated macrophages and microglia without a targeting ligand. HDTs are renally cleared intact in humans and no HDT related adverse events have been observed in 2 Phase 1 trials and a Phase 2 trial. Imaging with D-B483 enables the selection of patients. By using the same HD platform for both imaging and therapy, we can determine the amount of HDT delivered to the tumor without the need for biopsy enabling optimization of therapeutic benefit. HDTs also are retained for up to one month in the tumor while systemically cleared within 48 hr, further reducing the potential for systemic side effects. D-B483 Phase 1 will be launched in Q4 2021 followed by a pipeline of HDTs with mechanisms related to TLR4, TLR7, CSF1R, SHP2, and other targets.
Domain Therapeutics is a preclinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for immuno-oncology. With teams at work in France and Canada, Domain operates multiple technologies aimed at validating G Protein-Coupled Receptors (GPCRs) mediating immunosuppression, at discovering first-in-class or best-in-class therapies, small molecules and antibodies, and at developing them in the clinic to create a pipeline of high-value proprietary programs.
eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. We employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent. Research shows that this approach results in long lasting clinical remission in cancer patients and protective immunity against infections.
eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.
Geneos Therapeutics is a VC backed, clinical stage immuno-oncology biotech company that is enabling its GT-EPICTM neoantigen targeting platform to develop personalized immunotherapies for cancer patients. The GT-EPICTM platform allows Geneos to develop exquisitely personalized DNA-based therapies tailored to each patient’s unique tumor mutations. The versatility of the platform provides many advantages including 1) the ability to drive potent and broad T cell immune responses, 2) the capability to target an unprecedented number of neoantigens in a single formulation, and 3) a rapid manufacturing turnaround time. These are key differentiators that will drive the company, and the oncology space, into the next generation of immunotherapies.
Geneos is conducting an international, multi-center, GT-30 Phase Ib/IIa clinical program evaluating its personalized neoantigen-targeting vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer. GNOS-PV02, which is based on Geneos’ proprietary GT-EPIC™ platform, is a tumor-specific DNA plasmid product designed and manufactured for each patient based on their unique tumor mutations’ (neoantigens), identified by sequencing each patient’s tumor. In the trial, GNOS-PV02 is combined with a DNA plasmid encoded cytokine immunomodulator IL-12 (INO-9012) and PD-1 checkpoint inhibitor (pembrolizumab). The trial is being conducted at Mount Sinai, Johns Hopkins, and Auckland New Zealand.
Imagia is a digital healthcare company building a data-analytics platform that accelerates the discovery process of innovative healthcare solutions using data generated in real-world settings. The research enabled by the Imagia EVIDENS (™) platform generates cutting-edge artificial intelligence (AI) assets and invaluable insights for the pharmaceutical, biotech and medical-device industries, while preserving patient privacy. imagia.com
IMV Inc. [NASDAQ: IMV]
IMV is a Canadian biopharmaceutical company committed to improving the treatment of cancer and giving patients with difficult-to-treat cancer a chance to enjoy a long and healthy life.
NOXXON’s oncology-focused pipeline acts by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.
ONCURIOUS NV is a Belgium-based biotech company focused on developing innovative oncology treatments derived from a series of promising new targets that are designed to enhance T cell activity and migration and infiltration into resistant tumor sites, boosting the response to immunotherapy in the large numbers of patients who respond sub-optimally to existing treatment. More info can be found on the companies website.
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases and fight Covid-19. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases, and to fight the Covid-19 with our prophylactic vaccine program CoVepit.
PharmAbcine Inc. is a biotech company developing therapeutic antibodies to treat cancer, ocular, and vascular diseases by targeting angiogenesis or immuno-oncology areas. Our key molecules are olinvacimab/TTAC-0001 (anti-VEGFR2) which is currently in three clinical trials for rGBM and mTNBC. Our preclinical assets are PMC-309 (anti-VISTA), PMC-403 (ligand-independent TIE2 activator), PMC-401s (anti-Ang2) and PMC-005BL (anti-EGFRvIII).
Refuge Biotech is a novel differentiated synthetic biology company in immune-oncology leveraging “CRISPR interference/activation” in cell therapies to make more efficacious therapies for the treatment of cancers. Refuge is able to modulate expression of multiplexed gene targets programming cells to react to their environment. We have significant pre-clinical proof-of-concept data across various solid tumors and are moving towards bringing these therapies into clinic. refugebiotech.com
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.
VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor and it can be readily adapted to target a wide range of cancer-related antigens.
Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer.
VAXIMM has an ongoing clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab, as part of a scientific collaboration with Merck KGaA, Darmstadt, Germany.
VAXIMM also has a neoantigen program currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a strategic clinical trial collaboration with NEC Corporation for the development of personalized neoantigen cancer vaccines.
Exactis Innovation a pan-Canadian Center of Excellence in precision oncology is a publicly funded research network comprised of 16 major cancer centers. Our Mission is to advance Precision Oncology through cutting-edge clinical and translational research. Personalize My Treatment, a patient registry with over 6,200 active participants that is linked with 5 federated NGS laboratories and experience in longitudinal biomarker trials form the core of the Exactis infrastructure. As leaders in precision oncology our goal is to develop longer-term partnerships including innovative network-wide study platforms for the evaluation of combination IO treatments using adaptive basket approaches.
Orion Biotechnology Canada Ltd, is a clinical stage biopharmaceutical company focused on the discovery and development of precision engineered small protein therapeutics – a promising new class of drugs designed to modulate immune response and deliver the next generation of immunotherapy treatment for cancer and other serious diseases.
Treos Bio uses computational data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies. The Company has developed a unique ability to match the antigens expressed by a specific cancer to the individual patients’ target recognition mechanism. This technology aims to address the challenge of the variability of individual patient’s clinical responses to cancer immunotherapies. Treos’ lead candidate is PolyPEPI-1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer, co-developed with a candidate companion diagnostic. Treos is developing personalized immunotherapies for several types of solid tumors and has completed preclinical development of off-the-shelf PolyPEPI immunotherapies in ovarian, breast, bladder, gastric and lung cancers and melanoma. The Company is also developing an investigational COVID-19 peptide vaccine, PolyPEPI-SCoV-2. Treos launched in February 2017 and has raised $28 million Series A funding led by shareholders of BXR Group and recently closed a $14 million investment round led by Luminous Ventures.